underwriters expect to deliver the shares to investors on                  , 2017.J.P. MorganCowen and CompanyWells Fargo SecuritiesBairdProspectus dated                  , 2017Table of ContentsTable of contentsPageProspectus summary1Risk factors15Special note regarding forward-looking statements and market data73Use of proceeds75Dividend policy77Capitalization78Dilution80Selected financial data83Management's discussion and analysis of financial condition and results of operations85Business106Management150Executive compensation159Director compensation168Non-employee director compensation policy169Certain relationships and related party transactions170Principal stockholders172Description of capital stock175Shares eligible for future sale181Certain material U.S. federal income and estate tax considerations to non-U.S. holders183Underwriting187Legal matters195Experts195Where you can find more information195Index to consolidated financial statementsF-1Neither we nor the underwriters have authorized anyone to provide you with information other than that contained in this prospectus or any free writing prospectus prepared by
Translational Science Platform enables us to effectively and efficiently identify and develop new cancer immunotherapies.•Targeting T cells:Our lead product candidate, JTX-2011, is a clinical
depend on several factors, including the following:•successful completion of preclinical studies of JTX-4014 and any future product candidates;•successful completion of non-clinical toxicology studies that may be required for regulatory approval of JTX-2011;•acceptance of Investigational New Drug applications, or INDs, for our planned clinical trials or future clinical trials;•successful enrollment and completion of clinical trials;•demonstration that the combination of JTX-2011 with JTX-4014 provides the same clinical benefit as JTX-2011 combined with nivolumab;•demonstration of a benefit/risk profile for JTX-2011 and future products that is sufficient to support a successful Biologics License
and third-party payors;•effectively competing with other therapies;•obtaining and maintaining healthcare coverage and adequate reimbursement;•enforcing and defending intellectual property rights and claims;•successful completion of clinical confirmatory trials to verify clinical benefit, if applicable; and•maintaining a continued acceptable safety profile of the product candidates following approval.If
promising product or product candidate may diminish substantially, which could have a material adverse effect on our business prospects, financial condition, and results of operations.Clinical product development involves a lengthy and expensive process, with an uncertain outcome.
future clinical trials that could delay or prevent our ability to receive marketing approval or commercialize JTX-2011, JTX-4014 and any other future product candidates,
investigational new drugs that could halt their clinical development, prevent their marketing approval, limit their commercial potential or result in significant negative consequences.Undesirable or clinically unmanageable side effects could occur and cause us or regulatory authorities to interrupt, delay or halt clinical trials
comparable foreign regulatory authorities could order us to cease clinical trials or deny approval of JTX-2011, JTX-4014 and any other future product candidates for any or all targeted indications.
following:•a product candidate may not be deemed safe or effective;•FDA officials may not find the data from preclinical studies and clinical trials sufficient;•the FDA might not deem our or our third-party manufacturers' processes or facilities adequate for approval of our marketing
complying with complex and changing foreign regulatory, tax, accounting and legal requirements and the reduced protection of intellectual property rights in some foreign countries.Our failure to successfully identify, acquire, develop and commercialize additional products or
candidate that we acquire may require additional development efforts prior to commercial sale, including extensive clinical testing and approval by the FDA and comparable foreign regulatory
may fail to achieve the degree of market acceptance by physicians, patients, third-party payors and others in the medical community necessary for commercial success.If JTX-2011, JTX-4014 and any other future product candidates receive marketing approval, whether as a single agent or in combination with other
acceptance of JTX-2011, JTX-4014 and any future products, if approved for commercial sale, will depend on a number of factors, including:•efficacy and potential advantages compared to alternative treatments;•the ability to offer our products, if approved, for sale at competitive prices;•convenience and ease of administration compared to alternative treatments;•the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies;•the strength of marketing and distribution support;•sufficient third-party coverage or reimbursement, including of combination therapies;•adoption of a companion diagnostic and/or complementary diagnostic; and•the prevalence and severity of any side effects.Risks related to manufacturing, commercialization and reliance on third partiesWe depend on our collaboration with Celgene and may depend on collaborations with additional third parties for the development and commercialization of our product
product candidates in certain geographies for certain indications, which would harm our business prospects, financial condition, and results of operations.30Table of ContentsWe may seek to establish additional collaborations, and, if we are not able to establish them on commercially reasonable terms, we may have to alter our development and
These exclusivity and governance provisions may inhibit our development efforts and may materially harm our business, financial condition, results of operations and prospects.We rely and will rely on third parties to conduct our clinical trials for JTX-2011, JTX-4014 and any other future product candidates.
any other future product candidates in the subject indication would be harmed, our costs could increase and our ability to generate revenue could be delayed.We face significant competition and if our competitors develop and market products that are more effective, safer or less expensive than JTX-2011, JTX-4014 or any other
Any increased scrutiny could delay or increase the costs of obtaining marketing approval for JTX-2011, JTX-4014 and any other future product candidates.Healthcare legislative reform measures may have a material adverse effect on our business and results of operations.In the United States, there have been and continue to be a number of legislative initiatives to contain healthcare costs.
conducting preclinical studies and clinical trials;•the timing of, and the costs involved in, obtaining marketing approvals for JTX-2011, JTX-4014 and any other future product candidates